Abstract: This document provides guidance for the risk assessment under Regulation (EC) No1829/2003 of the unintended, adventitious or technically unavoidable presence in food and feed of low level of genetically modified plant material intended for markets other than in the European Union. In this context, the presence at low level is defined to be maximum 0.9% of genetically modified plant material per ingredient. This guidance is intended to assist applicants by indicating which scientific requirements of AnnexII of Regulation (EU) No503/2013 are considered necessary for the risk assessment of the presence at low levels of genetically modified plant material in food and feed. 
Summary
Following a request of the European Commission, the European Food Safety Authority (EFSA) provides guidance on the scientific requirements of Annex II of Regulation (EU) No 503/2013 considered necessary (and those not) to conclude on the safety of applications covering the adventitious or technically unavoidable presence at low level (0.9% or below per ingredient) of genetically modified plant material in food and feed intended for markets other than in the European Union (EU).
This guidance provides support to and should be read in conjunction with Regulation (EU) No 503/2013 and it is not intended to serve as a stand-alone guidance.
The characterisation of the transformation event and of its intended effects should be performed. Not all the scientific requirements of the Annex II of Regulation (EU) No 503/2013 aiming at identifying unintended effects are considered necessary on a routine basis, since the safety and nutritional impact of these effects on the ingredient are considered limited in the context of the presence of a genetically modified plant material at low level. These requirements include some data concerning the expression of the insert, in silico RNAi off-target searches, routine comparative analysis studies of the genetically modified plant; 90-day toxicity studies in rodents on the whole food and feed are not considered necessary.
On a case-by-case basis, when a hypothesis can be formulated for compositional changes that may impact the safety and nutritional characteristics of the ingredient, a targeted compositional analysis is requested. The experimental design, selection of endpoints and data analysis of such a targeted analysis would not need to follow all the scientific requirements of Annex II of Regulation (EU) No 503/2013. Comparative compositional studies performed according to Codex Alimentarius could support such assessment.
The applicant needs to justify the approach followed and to indicate what assumptions have been made during the risk assessment as well as the nature and magnitude of uncertainties.
Both acute and repeated exposure scenarios should be envisaged. The possible cumulative contribution to an ingredient from various genetically modified plants and derived products present at low level and showing similar traits should be considered.
Environmental risk assessments conducted under situations of the presence at low levels should follow the principles and approach outlined in the Genetically Modified Organisms Panel Guidance Document on the environmental risk assessments of genetically modified plants and other applicable EFSA guidelines. Genetically modified organisms (GMOs) and derived food and feed products are subject to a risk assessment and regulatory approval before they can enter the market in the EU. In this process, the role of the EFSA is to independently assess and scientifically advise risk managers on any possible risk that the use of GMOs may pose to human's and animal's health and the environment. EFSA's scientific advice is elaborated by its GMO Panel with the scientific support of specific working groups and EFSA scientists.
Detailed guidance was adopted by EFSA (2006) and updated in EFSA GMO Panel (2011a) to assist applicants in the preparation and the presentation of applications of food and feed from genetically modified (GM) 503/2013 states that by way of derogation, an application may be submitted that does not satisfy all the scientific requirements for the risk assessment of GM food and feed set out in Annex II, provided that 'particular information is not necessary owing to the nature of the genetic modification or of the product; or it is not scientifically necessary, or technically possible to supply such information'.
Genetically modified organisms and derived food and feed products not intended to be exported to the EU have been or are being developed for specific health or market needs in third countries. The accidental presence of some of these GMOs at low levels cannot completely be excluded in exports to the EU. In this context and in accordance with • the EFSA guidance should be applicable to the presence at low level of GMOs, independently of the existence or not of a third country risk assessment;
• applications submitted under this EFSA guidance should only concern GMOs developed for specific health or market needs in third countries and not intended for the EU market. Therefore, they should not cover GMOs for which a full scope application has been previously submitted;
• exposure scenarios through commodities, such as grains, beans, or through foods consumed whole and undiluted should be considered under this EFSA guidance (further clarification on this point is provided in Section 1.2 of this document);
• a cumulative risk assessment should be performed in case of similar traits present in the same crop in different applications submitted under this EFSA guidance;
• for stacks, the same principles as those referred to in Reg. (EU) 503/2013 will apply and the implementation of the 0.9% threshold should follow the same rules as for labelling purposes, i.e. the threshold applies to individual events. 
1.2.

Interpretation of the Terms of Reference
Following an exchange with the European Commission, it was further clarified that an application of a GMO at low level submitted under Reg. (EC) 1829/2003 (hereafter referred to as 'LL application') covers a request for the authorisation of a GMO 4 present at a level of maximum 0.9% per ingredient in any food and/or feed, due to adventitious or technically unavoidable circumstances.
For the purpose of this document, an ingredient (hereafter referred to as 'LL ingredient') is the mixture of the GMO subject of the LL application and the same plant species and/or derived product at the predefined proportion of a maximum of 0.9% and minimum of 99.1%, respectively.
It is assumed that in a LL application the GMO is present at a level of maximum 0.9% per LL ingredient from point of entry into the EU through the food/feed production and processing chain, up to the food (or feed) portion consumed.
Situations where a GMO can achieve levels higher than 0.9% per LL ingredient are therefore not in the remit of this guidance. This could be the case of GM fruits and vegetables (e.g. papaya, potatoes) constituting either a full portion or part of a consumed portion resulting in an exposure of consumers (or animals) to that GMO higher than 0.9%. Therefore, even if included in the European Commission mandate, these situations are not within the remit of this guidance.
The decision on whether a given GMO can constitute a LL application is a risk management issue, and it is therefore not in the remit of this guidance.
In its mandate, the European Commission referred to Codex Alimentarius guideline for the food safety assessment of Low Level Presence (LLP) of recombinant DNA plant material in food 5 as a document to consider during the development of this guidance. The GMO Panel took into consideration principles and requirements outlined in the above-mentioned document to develop this guidance. Some adaptations were needed to address the Terms of Reference of this mandate; these are summarised in Appendix A of this guidance.
2.
Data and methodologies
Data
In delivering this guidance, the GMO Panel took into account the requirements outlined in Reg. ( 
Methodologies
EFSA established an ad hoc Working Group of the GMO Panel to address the mandate on the risk assessment of the presence at low levels of GMOs not intended for the EU market in imported food and feed under the frame of Reg. (EC) 1829/2003. In accordance with the Terms of Reference of the mandate, the Working Group scrutinised which scientific requirements of Annex II of Reg. (EU) 503/2013 are necessary to conclude on the safety of GMOs present in food and feed at the adventitious or technically unavoidable level of maximum 0.9% per ingredient. Possible derogations from existing requirements were identified, and justified reasons provided.
In order to adequately take EU Member States and stakeholders comments into account, two consultations were organised in a stepwise manner. The first consultation (from 28 October to 9 December 2016) was dedicated to EU Member States. Following this consultation process, the document was revised by the GMO Panel and then opened for a second public consultation (from This guidance does not cover the risk assessment of GMOs for cultivation purposes, GM microorganisms, GM animals, GMOs for non-food/feed uses and novel foods as this is not in the scope of Reg. (EU) 503/2013. This guidance does not consider issues related to risk management (e.g. traceability, labelling and coexistence). Socioeconomic and ethical issues are also outside the scope of this guidance.
General considerations for the risk assessment of LL applications
The risk assessment strategy for standard GMO applications is driven by the comparative assessment principle, which aims to evaluate whether the GMO is as safe and as nutritious as traditionally cultivated crops (and derived products) with a history of safe use for consumers and/or animals (Codex Alimentarius, 2009; EFSA GMO Panel, 2011a) . Within this comparative frame, a standard GMO application is assessed assuming the possibility of a 100% replacement of the corresponding conventional crop and derived products. To support the assessment, the GMO Panel identified the scientific requirements and deployed a wide range of tools and methods (EFSA GMO Panel, 2011a), which have been incorporated into Annex II of Reg. (EU) 503/2013 by the European Commission and EU Member States.
In a LL situation as defined in this guidance, exposure to the GMO will be at maximum 0.9% per LL ingredient. This predefined threshold implies a lower exposure to the GMO than that foreseen in standard GMO applications. The adventitious or technically unavoidable circumstances leading to a LL situation do not exclude the possibility of repeated exposure of consumers/animals to the GMO. Therefore, both single and repeated exposure scenarios are considered.
Based on the above considerations and taking into account the Codex Alimentarius guideline for the 'Food safety assessment in situations of low-level presence of recombinant-DNA plant material in food' (Annex 3, adopted 2008), the GMO Panel considers that certain scientific requirements for the risk assessment of standard GMO applications are necessary in LL situations, others are not or should be adapted. Section 3.2 of this guidance describes in detail which scientific requirements of Annex II of Reg. (EU) 503/2013 are necessary and which are not to conclude on the safety of a GMO in a LL application.
For the risk assessment of LL applications of stacked events, the applicant will provide a risk assessment of each single transformation event or, in accordance with Article 3 (6) The molecular characterisation of the GM plant serves two purposes: first, it allows the characterisation of the transformation event, and second, it is the first step to detect potential unintended effects linked to the genetic modification.
In the case of LL situations, the exposure to the GMO is defined to be at a maximum 0.9% per ingredient, and therefore, some of the molecular characterisation data requirements specified in Annex II.II of Reg. (EU) 503/2013 are not considered necessary, or necessary only on a case-by-case basis. In the following sections, the rationale for considering whether specific requirements are necessary or not is described. Protein expression data obtained under the conditions in which the crop is grown as well as the description of the methods used for expression analyses (point 1.2.2.3(a)] and (e)) are considered necessary for characterising the GM plants in LL applications on single transformation events. However, only the expression levels from those part(s) of the plant used for food and feed purposes are considered needed to complete the risk assessment. Therefore, points 1.2.2.3(b) ('information on developmental expression of the insert during the life cycle of the plant') and 1.2.2.3(c) ('parts of the plant where the inserted/modified sequences are expressed') of Annex II of Reg. (EU) 503/2013 are not considered necessary in LL applications. The likelihood of off-target effects resulting from silencing approaches by RNAi expression large enough to raise safety concerns in a LL situation is considered negligible. Therefore, the in silico search for potential 'off-target gene(s)' described in point 1.2.2.3(e) is not considered necessary.
The requirements described in subsection 1. In the case of stacks, the GMO Panel considers that the likelihood for changes in the expression levels of the newly inserted sequences as a consequence of interactions between the events impacting the safety of the LL ingredient is negligible, given the defined presence of 0.9% of the stack per LL ingredient. Therefore, point 1.2.2.3(f) of Annex II of Reg. (EU) 503/2013 is not routinely required. On a case-by-case basis, when the nature or the characterisation of the transformation events combined in a stack suggests an interaction that may result in changes of the expression levels of the newly inserted sequences raising safety concerns in a LL situation, these data should be provided.
The scientific requirements in subsection 1.2.2.4 ('Genetic stability of the insert and phenotypic stability of the genetically modified plant') of Annex II. The comparative analysis of composition and agronomic and phenotypic characteristics constitutes, together with the molecular characterisation, the starting point to structure and conduct the risk assessment of food and feed from GM plants under Reg. (EC) 1829 /2003 (EFSA GMO Panel, 2011a . It aims at identifying the differences in composition (intended and unintended) between the GM plant and its conventional counterpart, and between the food and feed derived from the GM plant and those derived from the conventional counterpart. It also aims at identifying differences in agronomic performance and phenotypic characteristics (intended and unintended) between the GM plant and its conventional counterpart. The methodological approach to conduct the comparative assessment on GMOs is detailed in paragraph 1.3 of Annex II.II of Reg. (EU) 503/2013, including criteria for the selection of appropriate comparator, experimental design of field trials and statistical analysis of results, selection of endpoints to measure and effects of processing.
The GMO Panel considers that the scientific requirements on comparative analysis of Reg. (EU) 503/2013 can be adapted for LL applications. Since in LL situations the level of exposure of consumers and animals to the GMO is defined to be at a maximum 0.9% per LL ingredient, not all differences identified in the comparative analysis may be relevant.
As regards compositional analysis, the level of a compound in a LL ingredient is determined by the levels of such compound in the GMO and in the plant (and/or derived product) constituting the remaining part of the LL ingredient. The ratio between these two levels determines the extent to which the level of the compound of the GMO impacts the overall level of that compound in the LL ingredient. For example, if the level of a compound in the GMO is 100X larger than that of the ingredient without the GMO, the increase of the compound in the LL ingredient as compared to the ingredient without that GMO is approximately twofold (~1.891). 7 A decrease in the level of a compound in the GMO results into a level in the LL ingredient never lower than 0.991 folds with respect to the ingredient without the GMO. In Table 1 , other examples of how the 0.9% GMO can affect the overall level of a compound in a LL ingredient are shown.
On the basis of current knowledge, the GMO Panel is of the opinion that variations in the level of compound(s) in GMOs are generally not large enough to impact the nutritional or safety characteristics of an ingredient in LL situations, with the possible exception of GMOs with traits developed to improve nutrition (e.g. nutritionally enhanced crops, P erez- Massot et al., 2013; EFSA GMO Panel, 2014) or in cases of expected unintended compositional changes (e.g. EFSA GMO Panel, 2011b) .
Therefore, the GMO Panel considers that comparative compositional analysis in LL situations is only necessary in any of the following cases:
• the intended trait targets the composition of the GMO (e.g. nutritionally enhanced GMOs);
• a hypothesis for a relevant compositional change can be formulated based on available information from the hazard identification, such as in the case of unintended compositional changes anticipated by the precedent analyses;
• if new constituents, other than newly expressed protein(s), are produced in the GMO.
In these cases, a targeted comparative compositional analysis is needed to quantify differences of the GMO with respect to its conventional counterpart, confirming the hypothesis that triggered the analysis. The outcome of the analysis will be used to perform an exposure assessment and to provide information relevant for cumulative risk assessment (see Section 3.2.5.3 of this guidance).
When there is the expectation of interactions between the transformation events stacked by conventional crossing that could lead to compositional changes in the stack GMO possibly impacting the composition of the LL ingredient, experimental targeted compositional analysis is needed.
The inclusion of agronomic and phenotypic endpoints in the comparative assessment studies in Reg. (EU) 503/2013 is intended to identify unintended effects related to the genetic modification and to address plant biology and agronomic traits. Considering that the main objective of comparative analysis in the context of LL situations is to quantify target compositional differences in the GMO with respect to its conventional counterpart confirming the hypothesis that triggered the analysis, a comparative analysis of agronomic and phenotypic characteristics described in paragraph 1.3.5 of Annex II.II of Reg. (EU) 503/2013 is not considered necessary in the context of LL situations. On a case-by-case basis, a comparative analysis of agronomic and phenotypic characteristics may be needed to support the environmental risk assessment (ERA) (see Section 3.3 of this guidance). When a targeted comparative compositional analysis is needed, it should include a difference test in accordance with the 'Principles of experimental design' described in point 1.3.2.1(a) of the subsection Regarding the 'Specific protocols for experimental design' detailed in point 1.3.2.1(b) of the abovementioned subsection of Annex II.II of Reg. (EU) 503/2013, the GMO Panel considers that when needed, studies to obtain material for the targeted comparative compositional analysis should be conducted under conditions maximising change(s) expected in the composition of the GMO, according to the hypothesis triggering the analysis. Field trials and greenhouse studies could be fit for such purpose. This deviates from Reg. (EU) 503/2013, which always requires the performance of trials under representative field conditions. Furthermore, since in LL situations the estimation of equivalence limits is not considered necessary, the inclusion of reference varieties in the experimental design is not required.
In case of field trial studies, the number of sites to support the targeted comparative compositional analysis in LL applications can be less than the eight prescribed by Reg. (EU) 503/2013 but should be adequate to perform the subsequent risk assessment steps (i.e. exposure assessment and cumulative risk assessment).
Similarly, in case the targeted comparative compositional analysis is performed under greenhouse conditions, justifications for the specific conditions selected should be provided to demonstrate their adequacy to perform subsequent risk assessment steps (i.e. exposure assessment and cumulative risk assessment). Criteria used for the selection of specific study conditions (e.g. field trials or greenhouse studies) should be described and the choice scientifically and explicitly justified by the applicant.
All the other requirements detailed in point 1.3.2.1 (b) are considered necessary for both field trials and greenhouse studies.
The 'Statistical analysis' requirements laid down in subsection 1.3. Comparative assessment studies performed under non-EU regulatory frames: applicability in LL applications
The GMO Panel considers that comparative assessment studies in accordance with Codex Alimentarius (2009) In LL applications, comparative compositional analysis is considered necessary when the composition of the GMO is expected to impact on the nutritional or safety characteristics of the LL ingredient. In these situations, a targeted compositional analysis is requested and adaptations of the scientific requirements of Annex II.II Reg. (EU) 503/2013 as regards the experimental design, selection of endpoints and data analysis are indicated. The applicant should state the rationale for conducting the targeted compositional analysis, or justify why this was not conducted. When a targeted comparative compositional analysis is conducted, the applicant is requested to provide justification for the conditions used; to indicate whether the outcome of the targeted compositional analysis confirms the expectations and allows to properly quantify differences between the GMO and its conventional counterpart to perform the subsequent exposure assessment; to provide information relevant for cumulative risk assessment; and to indicate if further investigations are needed. In line with this paragraph of Reg. (EU) 503/2013 in LL situations the applicant should primarily base its risk assessment of the GM food and feed on the molecular characterisation and toxicological evaluation of the GMO, as above described. The GMO Panel considers that in LL situations a 90-day feeding study as requested in subsection 1.4.4.1 of Annex II.II of Reg. (EU) 503/2013 ('Testing of whole GM food and feed') is not needed to corroborate information on the toxicological characteristics of the whole GM food and feed in rodents and/or to reduce the remaining uncertainties, considering the limited exposure to the GMO. On a case-by-case basis, depending on the GMO characteristics and on the results from preceding analysis, a 90-day study might be necessary to test specific toxicological hypothesis. In line with subsections 1. However, in the case where there is the expectation of changes in the level of known endogenous allergens in the GMO impacting the allergenicity of the LL ingredient, these endogenous allergens should be analytically measured (see considerations in Section 3.2.3.3 of this guidance). In this case, the assessment of allergenicity of the food or feed from the GMO should be conducted according to requirements of paragraph 1. Considering that the scope of LL applications is limited to a level of maximum 0.9% of a GMO per LL ingredient, a nutritional assessment is not considered necessary on a routine basis (see Section 3.1.2 of this guidance) unless changes in the levels of constituents (i.e. compositional endpoints) in the GMO possibly impacting the nutritional characteristics of the LL ingredient are expected (see Section 3.2.3.3 of this guidance). In this case, these constituents should be analysed and nutritionally assessed. The GMO Panel considers that in such situation requirements of paragraph 1.6.2 of Annex II.II of Reg. (EU) 503/2013 ('Points to consider for the nutritional assessment of genetically modified food and feed') can be adapted as follows: point (a) the nutritional assessment should be focused on hypothesis-driven target compounds, taking into account their levels (see Section 3.2.3.3 of this guidance); point (b) should consider their bioavailability and biological efficacy; point (c) should consider the anticipated dietary intake of the ingredient without the GMO and the resulting nutritional impact of the GMO (at a maximum 0.9% incorporation) in the LL ingredient. The assessment should include both acute and repeated dietary intake scenarios.
For LL situations concerning stacks, the applicant should provide an assessment of the potential synergistic or antagonistic interactions between the events which may have a nutritional impact on the LL ingredient. In line with Reg. (EU) 503/2013, on a case-by-case basis, depending on the GMO characteristics and on the results from preceding analysis, nutritional studies on food and feed from the GMO might be appropriate to test specific hypothesis.
In the case nutritional assessment studies are needed in a LL application, requirements laid down in paragraphs 1.6.3 and 1. The conclusion of the nutritional assessment in a LL application should indicate if the GMO at maximum 0.9% incorporation in a LL ingredient has a nutritional impact on the LL ingredient after acute and repeated exposure. In a LL application, the exposure to the GMO is defined to be maximum 0.9% per ingredient, under acute or repeated intake scenarios. The GMO Panel considers that the exposure assessment requirements laid down in Annex II.II of Reg. (EU) 503/2013 should be based on this predetermined exposure level.
In particular, exposure considerations should focus on newly produced components (e.g. newly expressed proteins) and on constituent(s) showing levels altered enough to impact the nutritional or safety characteristics of the ingredient (see Section 3.2.3.3 of this guidance). The goal of the targeted comparative compositional analysis in a LL application is to quantify changes expected in the composition of the GMO, confirming the hypothesis that triggered the analysis. The applicant shall demonstrate that the targeted compositional analysis of the GMO has been carried out in accordance with the considerations presented in this guidance (see Section 3.2.3.3 of this guidance). In a LL application, this aspect of the risk characterisation should consider the data generated to estimate possible short-and long-term risks to human or animal health associated with the consumption of food/feed containing the LL ingredient. Requirements described in paragraph 3.2.3 of Annex II.II of Reg. (EU) 503/2013 are considered necessary, providing these are adapted to the specific context of the LL situation under assessment.
Post-market monitoring will be considered on a case-by-case basis. In accordance with the requirements of Annex II.II of Reg. (EU) 503/2013, the applicant should ensure that the final risk characterisation clearly demonstrates that the GMO does not impact the safety and nutritional characteristics of the LL ingredient (where it is unavoidably, adventitiously present at maximum 0.9%) to such an extent that the normal consumption of the LL ingredient would be nutritionally disadvantageous for consumers or animals.
The applicant should clearly indicate what assumptions have been made during the risk assessment in order to predict the probability of occurrence and severity of adverse effect(s) in a given population, and the nature and magnitude of uncertainties associated with establishing these risks.
Information justifying the inclusion or not of a proposal for labelling in the application is not required considering the scope of LL applications.
Cumulative risk assessment
The risk assessment of LL applications described in this guidance is carried out for a GMO present at a predefined maximum 0.9% exposure level per ingredient. In case of multiple LL applications for GMOs showing similar traits, the possible cumulative contribution of the various GMOs to the ingredient should be taken into consideration in the risk assessment, as required by the mandate (see Section 1.1 of this guidance). For example, if a similar trait intended for improving nutrition is expressed in different GMOs subject of different LL applications, the relative contribution to the ingredient of each of these GMOs should be taken into account to allow an estimation of their total contribution, via the addition of the respective trait-related constituent(s). Information from the outcome of the targeted compositional analysis (see Section 3.2.3.3 of this guidance) of each of these GMOs is relevant to establish the strategy to perform the cumulative assessment.
Environmental risk assessment
As mentioned in Reg. (EU) 503/2013, the ERA of GMOs or food/feed containing or consisting of GMOs should be performed according to the principles outlined in Annex II to Directive 2001/18/EC on the deliberate release into the environment of GMOs, and applicable GMO Panel Guidance Documents. The GMO Panel therefore recommends applicants to follow the principles and approach outlined in the GMO Panel Guidance Document on the environmental risk assessments of GM plants (EFSA GMO Panel, 2010) and other applicable EFSA guidelines (i.e. EFSA, 2017) to determine the data requirements for ERA of GM plants under LL situations.
ERAs conducted under LL situations should be case-specific (taking into account the biology of the plant species, the intended trait(s), the potential receiving environments and interactions among all three), and should begin with an explicit problem formulation where the GM plant is described using existing knowledge, and potential hazards and exposure routes are identified (OECD, 2013; Roberts et al., 2014) . Taking this information into account, applicants should identify which areas of risk need to be addressed and hence the data requirements to inform the risk assessment. Risk should then be characterised by testing specific hypotheses about the likelihood and severity of adverse environmental effects that may occur.
The problem formulation should focus on the following exposure pathways: (1) exposure of microbial communities to recombinant DNA in the gastrointestinal tract of animals fed GM plant material or recombinant DNA in faecal material (manure and faeces) of these animals; and (2) accidental release into the environment of imported viable material from the GM plant during transportation and processing.
In general, a comparative analysis of agronomic and phenotypic characteristics of the LL GM plant to identify potential hazards is not considered mandatory under LL situations, representing a derogation to Annex II requirements of Reg. (EU) 503/2013. However, such analysis may be needed to support the ERA on a case-by-case basis depending on the persistence, invasiveness and hybridisation potential of the LL GM plant.
Conclusions
This guidance indicates which scientific requirements of Annex II of Reg. (EU) 503/2013 are necessary to conclude on the safety of applications covering the unintended and technically unavoidable presence in food and feed of low level of GM plant material (0.9% or below per ingredient) intended for markets other than in the EU.
To this aim, a comprehensive characterisation of the transformation event and of its intended effects should be performed. Not all the scientific requirements of the Annex II of Reg. (EU) 503/2013 aiming at identifying unintended effects are considered necessary on a routine basis, since the safety and nutritional impact of these effects on the ingredient is considered limited in the context of presence of a GM plant material at low level.
On a case-by-case basis, when a hypothesis for relevant compositional changes can be formulated, a target compositional analysis is requested. The experimental design, selection of endpoints and data analysis of such a targeted analysis would not need to follow all the scientific requirements of Annex II of Reg. (EU) 503/2013. Comparative compositional studies performed according to Codex Alimentarius could support such assessment.
The applicant needs to justify the approach followed and to indicate what assumptions have been made during the risk assessment, as well as the nature and magnitude of uncertainties.
ERAs conducted under situations of presence at low levels should follow the principles and approach outlined in the EFSA Guidance Document on the environmental risk assessments of GM plants (EFSA GMO Panel, 2010) and other applicable EFSA guidelines.
-food commodities large in particle size (e.g. tomato, papaya), and commonly consumed whole; these are expected to constitute a less frequent situation. In this case, each particle of such food might constitute an entire consumed portion of the GMO.
The risk assessment strategy and methodology advocated by Codex Alimentarius (Codex Alimentarius, 2009, Annex 3) differs for the two dietary exposure scenarios, with compositional data (limited to key toxicants and allergens) required only for the second scenario. Instead, this GMO Panel guidance is requested to cover an exposure scenario for which a GMO is present at a level of maximum 0.9% per ingredient in the final food or feed.
